What if your delivery system could improve the effectiveness of your cancer therapeutic?

Talk to an Expert

Enabling New Possibilities
for Your Cancer Therapeutic

PharmaJet technology enables improved tissue distribution and cellular uptake of vaccines.

1, 2, 3

DNA vaccines delivered needle-free tend to elicit improved immunogenicity compared with needles.

2, 4, 5, 6, 7, 8

In oncology applications, PharmaJet technology can modulate the immune response by targeting dermal bioavailability.

2, 9

PharmaJet Partners:
Advancing Oncology Solutions

PharmaJet delivery systems are used in several of Nykode’s clinical trials for cancer vaccines, including cervical cancer, head and neck cancers, and metastatic solid tumors. 10

nykode therapeutics

Scancell’s SCIB1/iSCIB1+ cancer vaccines for melanoma are administered with PharmaJet delivery systems in a Phase II trial. 11

See Press Release

The PharmaJet Stratis needle-free system is today the only technology which has shown effective uptake of the DNA vaccine through intramuscular delivery allowing native cellular machinery to express the target antigen and induce a potent anti-tumour response.

– Lindy Durrant, Chief Scientific Officer at Scancell

See our Clinical Trials Pipeline

Partner with PharmaJet and discover a new way to enhance your cancer therapeutic.

Inquire About Partnerships

References

1.Bernelin-Cottet (2019) Viruses 2.Peng (2023) mBio 3.Meyer(2023) Vaccine X 4.Brocato (2021) Vaccine 5.Yadov (2023) J Med Virol 6.Gaudinski (2018) Lancet 7.Kwilas (2014) Curr Gene Ther 8.Ledesma-Feliciano (2023) Vaccines 9.Szymura (2024) Nat Commun 10.Hillemanns (2022) Clin Cancer Res 11.Paston (2024) CIMT Poster